In mammals, including humans, the cells that contract the heart muscle and enable it to beat do not regenerate after injury. After a heart attack, there is a dramatic loss of these heart muscle cells and those that survive cannot effectively replicate.

The first view of the physical mechanism of how a blood clot contracts at the level of individual platelets is giving researchers from the Perelman School of Medicine at the University of Pennsylvania a new look at a natural process that is part of blood clotting. A team led by John W.

The low efficacy of last year’s influenza vaccine can be attributed to a mutation in the H3N2 strain of the virus, a new study reports.

Notch is one of the most frequently mutated genes in chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the United States. It is also often mutated in other common B cell tumors, such as mantle cell lymphoma. However, the role of Notch in these cancers has been uncertain.

Seven University of Pennsylvania faculty members have been elected to the National Academy of Medicine (NAM), one of the nation’s highest honors in biomedicine. They are among 70 new U.S. and 10 international members of the globally renowned organization.

Noroviruses are the leading cause of non-bacterial gastroenteritis in the world and are estimated to cause 267 million infections and 20,000 deaths each year. This virus causes severe diarrhea, nausea, and stomach pain.

In 2014, new combination therapies to treat patients with metastatic melanoma hit the market, helping extend the lives of those with this aggressive disease. Yet unfortunately, after several months of treatment, almost all patients on the regimen eventually relapsed.

Chantell Evans, PhD, a postdoctoral fellow in the Perelman School of Medicine at the University of Pennsylvania, has been selected by the Howard Hughes Medical Institute (HHMI) as one of 15 early-career scientists in its first cohort of HHMI Hanna Gray Fellows.

Genetic, stem cell, and reproductive technologies that have the capability to fundamentally change our cells is challenging what is means to be human.

Penn Medicine’s Orphan Disease Center (ODC) announces a new partnership with the Foundation for Angelman Syndrome Therapeutics or FAST to study gene therapy approaches to treat Angelman syndrome (AS).